Characterization of in vivo resistance to osimertinib and JNJ-61186372, an EGFR/Met bi-specific antibody, reveals unique and consensus mechanisms of resistance

Characterization of in vivo resistance to osimertinib and JNJ-61186372, an EGFR/Met bi-specific antibody, reveals unique and consensus mechanisms of resistance

Approximately 10% of non-small cell lung cancer (NSCLC) patients in the United States and 40% of NSCLC patients in Asia have activating epidermal growth factor receptor (EGFR) mutations and are eligible to receive targeted anti-EGFR therapy. Despite an extension of life expectancy associated with th...

Full description

Bibliographic Details
Main Authors: Moores, Sheri L. (Author), Laquerre, Sylvie (Author), Emdal, Kristina Bennet (Contributor), Dittmann, Antje (Contributor), Reddy, Raven J. (Contributor), Lescarbeau, Rebecca S. (Contributor), White, Forest M. (Author)
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Massachusetts Institute of Technology. Department of Materials Science and Engineering (Contributor), White, Forest M (Contributor)
Format: Article
Language:English
Published: American Association for Cancer Research (AACR), 2018-11-19T17:01:25Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items